Skip to main content
Premium Trial:

Request an Annual Quote

Affy Expands GeneChip Deal with GlaxoSmithKline

NEW YORK, Sept 10 – Affymetrix said Monday that it had expanded its agreement to provide GlaxoSmithKline with its GeneChip technology. 

Under the terms of the deal, Glaxo’s research centers will be able to receive customized GeneChip arrays in smaller format sizes, providing them with lower cost arrays for high-throughput studies.

The deal reflects a new Affymetrix effort to offer specialized arrays at reduced prices.

"GSK's broader adoption of Affymetrix' GeneChip technology validates our belief that the market is shifting towards pre-synthesized oligonucleotide arrays," Susan Siegel, president of Affymetrix, said in a statement.

"By leveraging our unique and flexible wafer-based manufacturing process, we are able to provide chips at the lowest cost per datapoint in the industry with content intended to meet specific needs," Siegel added. 

Financial terms of the deal were not disclosed. 

The Scan

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.

Effectiveness May Decline, Data From Israel Suggests

The New York Times reports that new Israeli data suggests a decline in Pfizer-BioNTech SARS-CoV-2 vaccine effectiveness against Delta variant infection, though protection against severe disease remains high.

To See Future Risk

Slate looks into the use of polygenic risk scores in embryo screening.

PLOS Papers on Methicillin-Resistant Staphylococcus, Bone Marrow Smear Sequencing, More

In PLOS this week: genomic analysis of methicillin-resistant Staphylococcus pseudintermedius, archived bone marrow sequencing, and more.